Parmax Pharma Ltd.

32.00 -0.59 ▼-1.8%

23 February 2024, 03:40:00 PM
Volume: 1,074

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.parmaxpharma.com
Market Cap 11.97 Cr.
Enterprise Value(EV) 17.68 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -11.03 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.89 Trailing Twelve Months Ending 2023-12
Book Value / Share 1.20 Trailing Twelve Months Ending 2023-12
Price to Book Value 27.03 Calculated using Price: 32.50
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 0.37 Cr. 3,741,300 Shares
FaceValue 10
About Parmax Pharma Ltd.
Parmax Pharma was incorporated on November 02, 1994. The certificate of commencement of business was received by the company on March 10, 1995.The IPO of the company was January 30, 1996 with 5100800 shares of Rs10/-each. The promoters were earlier in manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The company then discontinued its business activities for few years due to various reasons. The company also plans to extend its activity in formulation of Tablets, Capsules, Ointments, & Injectable.

Parmax Pharma Ltd. Delivery

Delivered Qty
Traded Qty

Parmax Pharma Ltd. Performance

1 Day
-1.81%
1 Week
+1.75%
1 Month
-1.60%
3 Month
+4.20%
6 Month
+10.31%
1 Year
-7.51%
2 Year
-30.36%
5 Year
+84.97%
10 Year

Parmax Pharma Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 0.7 -0.12 -0.28 0.02 3.71 18.19 22.55 3.38 -2.26
Return on Capital Employed (%) 0.88 0.28 0.18 0.81 1.96 10.19 16.25 6.62 3.93
Return on Assets (%) 0.45 -0.08 -0.12 0 0.43 2.11 3.45 0.7 -0.58

Parmax Pharma Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 4 5 5 5 5 5 6 6 6 3
Non Curr. Liab. 1 0 1 2 5 5 6 5 5 6
Curr. Liab. 0 0 2 10 10 11 11 7 7 7
Minority Int.
Equity & Liab. 5 5 8 17 20 21 23 18 18 15
Non Curr. Assets 3 3 3 6 9 10 11 11 10 10
Curr. Assets 2 2 4 9 9 9 10 7 8 6
Misc. Exp. not W/O 1 1 1 2 2 2 1 1 0
Total Assets 5 5 8 17 20 21 23 18 18 15

Parmax Pharma Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 12 12 21 26 18 15 13
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 12 12 21 26 18 15 13
Total Expenditure 0 0 0 -11 -11 -19 -23 -16 -13 -15
PBIDT 0 0 0 1 1 2 4 3 2 -2
Interest 0 0 0 0 0 0 -1
Depreciation -1 -1 -1 -2 -2 -2 -2
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 1 0 0 -4
Adjusted EPS 0 0 0 0 1 2 0 0 -11

Parmax Pharma Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -1 4 1 3 4 1 0
Cash Fr. Inv. 0 -4 -3 -2 -3 -2 -1
Cash Fr. Finan. 0 0 1 1 3 0 0 -1 0
Net Change 0 0 0 1 1 0 1 -2 -1
Cash & Cash Eqvt 0 0 0 0 1 2 2 3 1 0

Parmax Pharma Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80
Public 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Parmax Pharma Ltd. Announcements

Tue, 20 Feb 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss share certificates
Wed, 14 Feb 2024
Financial Results For Quarter And Nine Months Ended 31.12.2023
Financial statements for quarter and nine months ended on 31.12.2023
Wed, 14 Feb 2024
Board Meeting Outcome for Financial Results For Quarter And Nine Months Ended 31.12.2023
Financial results for quarter and nine months ended 31.12.2023

Parmax Pharma Ltd. Technical Scans

Thu, 22 Feb 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Closing Near 50 SMA Closing Near 50 SMA
Closing Near 20 SMA Closing Near 20 SMA

Parmax Pharma Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 373,756.40 1,561.25 +0.2%
Cipla Ltd. 117,370.75 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. 106,155.83 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. 97,309.86 6,774.05 +0.1%
Divi's Laboratories Ltd. 96,809.75 3,648.10 +0.1%
Zydus Lifesciences Ltd. 91,584.23 923.25 +2.1%
Torrent Pharmaceuticals Ltd. 88,295.34 2,626.95 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.97 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-12 31.65 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.30 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.28 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 70.00 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 30.80 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.10 2,626.95 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.99 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-12 4.53 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.95 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 7.43 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.71 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.35 2,626.95 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,626.95 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,626.95 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,626.95 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,626.95 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,626.95 +0.7%

Parmax Pharma Ltd. FAQ's

What is Parmax Pharma share price?

Can I buy Parmax Pharma shares now?

What is the Market Cap of Parmax Pharma?

What are the key metrics to analyse Parmax Pharma?

What is the 52 Week High and Low of Parmax Pharma?

What is the trend of Parmax Pharma share price?